Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"OrsoBio","sponsor":"Mitobridge","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Phenex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces Presentation of Five Abstracts at AASLD\u2019s The Liver Meeting\u00ae 2022 Highlighting Programs for Severe Metabolic Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by OrsoBio

    Menu

    OrsoBio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              OrsoBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

              Details:

              The financing will support the advancement of OrsoBio’s obesity-focused portfolio, including TLC-3595, a potent, selective, small molecule, allosteric inhibitor of acetyl-CoA carboxylase 2 (ACC2).

              Lead Product(s): TLC-3595

              Therapeutic Area: Endocrinology Product Name: TLC-3595

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Longitude Capital

              Deal Size: $60.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases

              Details:

              TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and NASH.

              Lead Product(s): TLC-6740

              Therapeutic Area: Nutrition and Weight Loss Product Name: TLC-6740

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes

              Details:

              TLC-3595 is a novel and selective ACC2 inhibitor designed to treat type 2 diabetes by increasing FAO, reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver

              Lead Product(s): TLC-3595

              Therapeutic Area: Endocrinology Product Name: TLC-3595

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

              Details:

              OrsoBio has recently acquired novel compounds and intellectual property for four programs, including inhibitors of acetyl-CoA carboxylase-2 (TLC-3595), liver X receptor, and aminocarboxymuconate semialdehyde decarboxylase, as well as a portfolio of mitochondrial protonophores.

              Lead Product(s): TLC-3595

              Therapeutic Area: Endocrinology Product Name: TLC-3595

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company

              Details:

              ACMSD is a key enzyme involved in the de novo synthesis of NAD+, which is critical to mitochondrial function via maintenance of cellular redox state. TLC-065, is being advanced for the treatment of a range of metabolic and inflammatory liver and kidney disorders.

              Lead Product(s): TLC-065

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TLC-065

              Highest Development Status: Preclinical Product Type: Undisclosed

              Recipient: Mitobridge

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes

              Details:

              TLC-3595 (formerly S-723595), a novel and selective ACC2 inhibitor, is designed to treat type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver.

              Lead Product(s): TLC-3595

              Therapeutic Area: Endocrinology Product Name: TLC-3595

              Highest Development Status: Phase I Product Type: Undisclosed

              Recipient: Shionogi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals

              Details:

              TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.

              Lead Product(s): TLC-2716

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Phenex Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders

              Details:

              TLC-1235, a novel, controlled-release mitochondrial protonophore, increases energy expenditure and is expected to have broad, systemic metabolic and cardiovascular benefits, including improved insulin sensitivity, NASH, dyslipidemia, and weight loss.

              Lead Product(s): TLC-1235

              Therapeutic Area: Dermatology Product Name: TLC-1235

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Yale University

              Deal Size: $2.3 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders

              Details:

              TLC-6740 is a novel, liver-targeted mitochondrial protonophore in development for the treatment of severe lipodystrophies and other metabolic disorders. Based on active hepatic uptake and mitochondrial protonophoric activity.

              Lead Product(s): TLC-6740

              Therapeutic Area: Dermatology Product Name: TLC-6740

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Samsara BioCapital

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OrsoBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders

              Details:

              TLC-2716 is a liver-targeted inverse agonist of the Liver X Receptor (LXR) for the treatment of severe hypertriglyceridemia, familial hypercholesterolemia and NASH.

              Lead Product(s): TLC-2716

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY